81
Participants
Start Date
February 23, 2021
Primary Completion Date
February 28, 2026
Study Completion Date
February 28, 2026
ABBV-637
Intravenous (IV) Infusion
Docetaxel
Intravenous (IV) Infusion
Osimertinib
Oral Tablets
Linkou Chang Gung Memorial Hospital /ID# 225946, Taoyuan
National Cheng Kung University Hospital /ID# 225944, Tainan City
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 243345, Kaohsiung City
Wollongong Hospital /ID# 228350, Wollongong
Austin Health /ID# 225638, Heidelberg
National Cancer Center /ID# 231887, Goyang-si
AP-HM - Hopital de la Timone /ID# 225779, Marseille
Centre Georges François Leclerc /ID# 226760, Dijon
Virginia Cancer Specialists - Fairfax /ID# 225693, Fairfax
Hospital Universitario Fundacion Jimenez Diaz /ID# 225975, Madrid
Hospital Universitario 12 de Octubre /ID# 225977, Madrid
Carolina BioOncology Institute /ID# 225358, Huntersville
Hospital Universitario Puerta de Hierro - Majadahonda /ID# 226096, Majadahonda
Hospital Universitario Virgen de la Victoria /ID# 225978, Málaga
National Taiwan University Hospital - Hsinchu branch /ID# 243610, Hsinchu
Institut Claudius Regaud /ID# 225780, Toulouse
Institut Bergonie /ID# 225778, Bordeaux
Washington University-School of Medicine /ID# 225698, St Louis
Institut Curie /ID# 225829, Paris
South Texas Accelerated Research Therapeutics /ID# 225359, San Antonio
Rambam Health Care Campus /ID# 225586, Haifa
The Chaim Sheba Medical Center /ID# 225585, Ramat Gan
Dana-Farber Cancer Institute /ID# 231209, Boston
Lifespan Cancer Institute at Rhode Island Hospital /ID# 226145, Providence
NHO Nagoya Medical Center /ID# 244412, Nagoya
National Cancer Center Hospital East /ID# 225725, Kashiwa-shi
Duplicate_National Hospital Organization Shikoku Cancer Center /ID# 240821, Matsuyama
National Hospital Organization Kyushu Cancer Center /ID# 240761, Fukuoka
National Cancer Center Hospital /ID# 225724, Chuo-ku
Asan Medical Center /ID# 231886, Seoul
Samsung Medical Center /ID# 231888, Seoul
Yonsei University Health System Severance Hospital /ID# 233774, Seoul
Hospital Universitario Vall d'Hebron /ID# 225976, Barcelona
Lead Sponsor
AbbVie
INDUSTRY